At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 23 enrolled
Drug / intervention
pazopanib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
In Brief
A Phase 1 clinical trial evaluating pazopanib and everolimus for Solid Tumor and Kidney Cancer. Completed, enrolled 23 participants across 2 sites.
Detailed Summary
This research study is evaluating the combination of pazopanib and everolimus in patients that have a malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective, or metastatic or locally advanced unresectable kidney cancer. In this research study the investigators are testing the safety of the combination of pazopanib and everolimus and finding the appropriate doses to use for further studies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Kidney Cancer
CountriesUnited States
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartJan 2011
Primary CompletionMar 2017
TodayJul 2026
First PostedAug 18, 2010
Enrollment StartJan 1, 2011
Primary CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 15.9 years ago
Interventions
pazopanibdrug
everolimusdrug